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Abstract
Background: Pneumonia is still the leading cause of death among children in Africa, and pneumococcal serotypes 1
and 5 are frequently isolated from African children with invasive pneumococcal disease below the age of 5 years. The
immunogenicity, safety and reactogenicity of 3-dose primary vaccination with the 10-valent pneumococcal non-
typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) were evaluated in infants in Mali and Nigeria.
Methods: In an open, randomized, controlled study, 357 infants received DTPw-HBV/Hib and OPV primary vaccination
with (PHiD-CV group) or without (control group) PHiD-CV co-administration at 6, 10 and 14 weeks of age. Pneumococcal
antibody responses and opsonophagocytic activity (OPA) were measured and adverse events (AEs) recorded.
Results: One month post-dose 3, ≥ 97.2% of PHiD-CV-vaccinated infants had an antibody concentration ≥ 0.2 μg/
mL for each vaccine pneumococcal serotype except for 6B (82.0%) and 23F (87.6%) versus < 10% in the control
group except for serotypes 14 (35.7%) and 19F (22.5%). For each vaccine serotype, ≥ 93.3% of PHiD-CV recipients
had an OPA titre ≥ 8, except for serotypes 1 (87.6%) and 6B (85.4%), compared to < 10% in the control group,
except for serotypes 7F (42.9%), 9V (24.1%) and 14 (24.5%). Anti-protein D geometric mean antibody concentrations
were 3791.8 and 85.4 EL.U/mL in the PHiD-CV and control groups, respectively. Overall incidences of solicited and
unsolicited AEs were similar between groups.
Conclusions: In sub-Saharan African infants, PHiD-CV was immunogenic for all vaccine pneumococcal serotypes
and protein D. Vaccine tolerability was generally comparable between the PHiD-CV and control groups.
Trial Registration: ClinicalTrials.gov identifier: NCT00678301.
Background
In 2008, infectious diseases caused 68% of the estimated
8.8 million deaths in children younger than 5 years, with
the largest percentage (18%) due to pneumonia [1].
Nearly half of pneumonia-related deaths in this age
group were in sub-Saharan Africa. In 2008, in Mali and
Nigeria alone, pneumonia caused almost 200,000 deaths
in children below 5 years of age. Due to the high burden
of childhood pneumonia in this region, donors such as
the Global Alliance for Vaccines and Immunization
(GAVI) support the introduction of pneumococcal con-
jugate vaccines in low-income African countries [2].
The contribution of Streptococcus pneumoniae to
childhood pneumonia has been difficult to define given
problems in establishing the aetiology of paediatric
lower respiratory tract infection [3]. Studies that
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evaluated the efficacy of different pneumococcal conju-
gate vaccines against X-ray confirmed consolidated
pneumonia in young children showed a 17% to 37%
reduction, irrespective of aetiological agent [4-8]. Pneu-
mococcal serotypes 1 and 5, which are not contained in
the 7-valent pneumococcal CRM197 conjugate vaccine
(7vCRM; Prevenar/Prevnar™, Pfizer Inc., New York,
USA), are known to play an important role in childhood
pneumococcal disease in Africa [9], where they are esti-
mated to cause 22% of invasive pneumococcal disease
(IPD) [10]. However, one study in 106 children with
IPD in Mali reported over half (54%) of invasive disease
cases were caused by serotype 5 [11].
The 10-valent pneumococcal non-typeable Haemophilus
influenzae protein D conjugate vaccine (PHiD-CV; Syn-
florix™, GlaxoSmithKline [GSK] Biologicals, Rixensart,
Belgium) contains pneumococcal serotypes 1, 5 and 7F in
addition to the 7 serotypes included in 7vCRM (serotypes
4, 6B, 9V, 14, 18C, 19F, 23F). PHiD-CV also contains
recombinant protein D as carrier protein for 8 of the 10
serotypes, which is derived from a cell surface lipoprotein
of non-typeable Haemophilus influenzae (NTHi) that is
highly conserved in both capsulated and non-capsulated
strains [12-14]. PHiD-CV has been shown in studies con-
ducted in Europe, Asia and Latin America to be immuno-
genic and well tolerated when administered in different
primary vaccination schedules and when co-administered
with other routine paediatric vaccines [15-22].
This is the first report of the assessment of PHiD-CV in
an African population. We studied the immunogenicity,
safety and reactogenicity of PHiD-CV when used for pri-
mary vaccination of infants in Mali and Nigeria according
to the vaccination schedule at 6, 10 and 14 weeks of age,
as used in the Expanded Program on Immunization (EPI)
in both countries.
Methods
Study Objectives and Vaccines
The objectives of this phase III, randomized, open, con-
trolled study were to assess the immunogenicity, safety
and reactogenicity of 3-dose primary vaccination with
PHiD-CV (Synflorix™) in sub-Saharan Africa. PHiD-CV
contained 1 μg of each capsular polysaccharide for pneu-
mococcal serotypes 1, 5, 6B, 7F, 9V, 14 and 23F, and 3 μg
for serotype 4 conjugated individually to NTHi protein D,
3 μg of serotype 18C capsular polysaccharide conjugated
to tetanus toxoid, and 3 μg of serotype 19F capsular poly-
saccharide conjugated to diphtheria toxoid. PHiD-CV was
co-administered with combined diphtheria-tetanus-whole-
cell pertussis-hepatitis B/Haemophilus influenzae type b
(DTPw-HBV/Hib; Zilbrix™ Hib, GSK Biologicals, Rixen-
sart, Belgium) and oral live attenuated poliovirus vaccines
(OPV; Polio Sabin™, GSK Biologicals, Rixensart, Belgium).
DTPw-HBV/Hib contained ≥ 30 IU diphtheria toxoid, ≥
60 IU tetanus toxoid, ≥ 4 IU killed Bordetella pertussis,
10 μg recombinant hepatitis B surface antigen (HBs) and
2.5 μg Hib polysaccharide polyribosylribitol phosphate
(PRP) conjugated to 5-10 μg tetanus toxoid. OPV con-
tained 106 TCID50 poliovirus type 1, 10
5 TCID50 polio-
virus type 2 and 105.5 TCID50 poliovirus type 3. PHiD-CV
and DTPw-HBV/Hib were injected into the anterolateral
region of the right and left thigh, respectively, and OPV
was administered orally.
Study Setting, Participants and Ethics
The study was conducted between June 2008 and
December 2009 at 2 study sites. In Mali, the research
team was based in the community health centre of the
rural town of Oulessebougou and infants were recruited
while visiting the local vaccination centre for their first
DTPw-HBV/Hib dose. In Nigeria, the study was con-
ducted in a purpose-built research suite at the Lagos
State University Teaching Hospital, Ikeja, by the Depart-
ment of Community Health and Primary Health Care.
Infants were recruited from the daily immunization clinic
and primary healthcare clinics around the hospital. Eligi-
ble subjects were healthy infants aged between 6 and 10
weeks at the time of first vaccination.
Written informed consent was obtained from a parent
or legal guardian or the thumb print of an illiterate par-
ent/guardian was obtained on the consent form, counter-
signed by an independent, literate witness. The trial was
conducted according to Good Clinical Practice and the
Declaration of Helsinki (Somerset West, 1996 version)
and the protocol was reviewed and approved in Mali by
the Ethical Committee of the Faculty of Medicine, Phar-
macy and Dentistry of the University of Bamako and in
Nigeria by the Health Research and Ethics Committee of
the Lagos State University Teaching Hospital, Ikeja,
Lagos. Authorization to conduct the study was obtained
from the Ministry of Health in Mali and the National
Agency for Food and Drug Administration and Control
in Nigeria.
Randomization
Infants were randomized (2:1 treatment allocation) to
receive 3 doses of PHiD-CV co-administered with
DTPw-HBV/Hib and OPV (PHiD-CV group) or 3 doses
of DTPw-HBV/Hib and OPV without PHiD-CV co-
administration (control group) at 6, 10 and 14 weeks of
age. A randomization list generated at GSK Biologicals,
Rixensart, using a standard SAS® program was used to
number the vaccines with a blocking scheme to ensure
that balance between treatment groups was maintained.
At the first vaccination visit, after verification of eligibil-
ity criteria, subjects received the vaccine dose with the
lowest number still available at the study centre and the
number used was recorded by the investigator.
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Immunogenicity Assessment
Blood samples were collected before vaccination and 1
month post-dose 3 and serum samples were stored at
-20°C until analysis. GSK’s 22F-inhibition enzyme-linked
immunosorbent assay (22F-ELISA) with an assay cut-off
of 0.05 μg/mL was used to measure anti-pneumococcal
serotype-specific total IgG concentrations. Pneumococcal
antibody responses were also analyzed using the thresh-
old antibody concentration of 0.2 μg/mL, which is
equivalent to the World Health Organization (WHO)
recommended reference value of 0.35 μg/mL with the
non-22F ELISA [23-25]. Opsonophagocytic activity
(OPA) was measured on a random subset of 50% of the
post-dose 3 samples (as planned in the protocol), using
the OPA assay described previously, with a cut-off opso-
nic titre of 8 [26,27]. Results were presented as the reci-
procal of dilution of serum (opsonic titre) able to sustain
50% killing of live pneumococci under the assay condi-
tions. Antibodies against NTHi protein D were measured
by a validated in-house ELISA with an assay cut-off of
100 ELISA units/mL (EL.U/mL). Serological responses
against the co-administered DTPw-HBV/Hib vaccine
were measured post-dose 3 in a subset of 50% of infants
in the PHiD-CV group (those not tested for OPA as
planned in the protocol) and all subjects in the control
group. Validated ELISA assays were used with the follow-
ing cut-off values: anti-PRP, 0.15 μg/mL; anti-diphtheria
toxoid, 0.1 IU/mL; anti-tetanus toxoid, 0.1 IU/mL; anti-B.
pertussis, 15 EL.U/mL; anti-HBs, 10 mIU/mL. Immune
responses against the co-administered OPV vaccine were
documented previously [28] and were therefore not
assessed in our study.
Safety Assessment
Local (pain, redness, swelling at the injection site) and
general (fever, drowsiness, irritability, loss of appetite)
symptoms were actively solicited for 4 days following
each vaccine dose and were evaluated in all subjects
using diary cards that were completed during daily home
visits by study physicians (Mali) or study field workers
(Nigeria). The field workers in Nigeria, who were selected
from the community based on their willingness to parti-
cipate, were trained on study procedures before and at
regular intervals during the study.
Other adverse events (AEs) were recorded within a 31-
day follow-up period after each vaccine dose and serious
adverse events (SAEs), defined as any medical event result-
ing in death, any life-threatening event or any event caus-
ing disability, or requiring hospitalization or prolongation
of hospitalization, were recorded during the entire study
period up to 1 month after the third dose.
The intensity of each solicited AE was graded on a
scale from 0 to 3. Pain at the injection site was consid-
ered to have a grade 3 intensity if the child cried when
the limb was moved/was spontaneously painful, redness
and swelling at the injection site if the diameter was > 30
mm and fever if axillary temperature was > 39.5°C. Irrit-
ability was considered of grade 3 intensity if the child
cried and could not be comforted/prevented normal
activity, and loss of appetite was considered grade 3 if the
child did not eat at all. Grade 3 intensity for all other
symptoms and AEs was defined as preventing normal
everyday activity and/or causing parents/guardians to
seek medical advice.
All solicited local symptoms were defined in the proto-
col to be considered causally related to vaccination. For
all other AEs, assessment of causal relationship to vacci-
nation was based on the investigator’s clinical judgment.
Use of therapeutic and prophylactic antipyretic medica-
tion was recorded within 4 days following each vaccine
dose.
Statistical Analysis
Immunogenicity analyses were performed on the accord-
ing-to-protocol (ATP) immunogenicity cohort, defined as
vaccinated subjects who met all eligibility criteria, com-
plied with the protocol-defined procedures and with at
least 1 antibody assay result available. To obtain 300 evalu-
able subjects for the ATP immunogenicity analysis (200 in
the PHiD-CV group and 100 in the control group), the
target sample size was 345 enrolled subjects (230 in the
PHiD-CV group and 115 in the control group). ELISA
geometric mean antibody concentrations (GMCs), geo-
metric mean OPA titres (GMTs) and percentages of chil-
dren reaching the predefined immunological thresholds
were determined with 95% confidence intervals (95% CIs).
Seropositivity/seroprotection rates and exact 95% CIs (cal-
culated from Proc StatXact 8.1) were determined for anti-
bodies against DTPw-HBV/Hib antigens. The safety
analysis was performed on the total vaccinated cohort.
Incidences of AEs were calculated with exact 95% CIs.
Weight-for-age Z-scores were calculated based on the




Three hundred and sixty-five infants were enrolled of
which 358 were randomized (238 in Mali and 120 in
Nigeria) and 357 received at least 1 study vaccine dose
(Figure 1). Subject recruitment started first in Mali and
to ensure that the total target sample size would be
reached, enrolment in that country continued until
recruitment was also initiated in Nigeria. As a conse-
quence, 8 more subjects than planned were enrolled and
randomized in Mali. In Nigeria, 5 more subjects than
planned were enrolled and randomized. There was some
reluctance to withhold vaccination with PHiD-CV from
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these infants for whom informed consent had already
been provided, since PHiD-CV had in the mean time
been licensed in Europe. The study was completed by
347 infants (231 PHiD-CV, 116 control group). Reasons
for withdrawal were consent withdrawal not due to an
AE (n = 4) or move out of the study area (n = 4) in the
PHiD-CV group, and loss to follow-up (n = 1) or non-
compliance with study timelines (n = 1) in the control
group.
The ATP immunogenicity cohort included 329 infants
(217 PHiD-CV, 112 control group); reasons for exclu-
sion from this cohort are given in Figure 1. The demo-
graphic characteristics of the PHiD-CV and control
groups were comparable (Table 1). All infants were
DTP, diphtheria-tetanus-pertussis; ATP, according-to-protocol 
*These 10 infants (8 in PHiD-CV group, 2 in control group) had no serological data available post-
dose 3 as they were withdrawn from the study because of consent withdrawal not due to an AE (n 
= 4) or move out of the study area (n = 4) in the PHiD-CV group, and loss to follow-up (n = 1) or 
non-compliance with study timelines (n = 1) in the control group 
Randomized and vaccinated (N = 357) 
Total vaccinated cohort
PHiD-CV group, N = 239 Control group, N = 118 
22 exclusions from ATP cohort:  
8 – no serological data post-dose 3* 
6 – not randomized correctly 
3 – protocol (inclusion/exclusion criteria) 
violation 
2 – study vaccine not administered 
according to protocol 
2 – forbidden medication administration 
1 – non-compliance with blood sampling 
schedule 
N = 217 
ATP immunogenicity cohort 
N = 112 
ATP immunogenicity cohort 
6 exclusions from ATP cohort:  
2 – no serological data post-dose 3* 
1 – protocol (inclusion/exclusion criteria) 
violation 
1 – study vaccine not administered 
according to protocol 
2 – forbidden medication administration 
Enrolled (N = 365) 
Randomized (N = 358) 
7 infants not randomized as non-eligible due to:  
2 – blood transfusion 
2 – did not return 
1 – preterm at birth 
1 – previous DTP vaccination 
1 – consent withdrawal 
1 infant did not receive study vaccines due 
to unsuccessful phlebotomy
Figure 1 Trial profile.
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African. Subjects were considered to be clinically healthy
at study entry according to the investigators. The mean
weight-for-age Z-score was -0.50 ± 1.13 at the first vac-
cination visit and did not considerably change at the fol-
lowing visits (Table 1).
Immune Responses to Primary Vaccination
Before vaccination, percentages of infants with antibody
concentration ≥ 0.2 μg/mL were consistent between
groups for each of the vaccine pneumococcal serotypes,
ranging from 14.8% to 87.9% in the PHiD-CV group
and 16.1% to 84.5% in the control group (Table 2). One
month post-dose 3, for each of the vaccine pneumococ-
cal serotypes, at least 97.2% of infants in the PHiD-CV
group had an antibody concentration ≥ 0.2 μg/mL,
except for serotypes 6B (82.0%) and 23F (87.6%), com-
pared to less than 10% of infants in the control group,
except for serotypes 14 (35.7%) and 19F (22.5%) (Table
2). At least 93.3% of infants in the PHiD-CV group had
an OPA titre ≥ 8, except for serotypes 1 (87.6%) and 6B
(85.4%), compared to less than 10% in the control
group, except for serotypes 7F (42.9%), 9V (24.1%) and
14 (24.5%) (Table 3). For the cross-reactive serotypes 6A
and 19A, 25.8% and 43.8% of PHiD-CV recipients,
respectively, had an antibody concentration ≥ 0.2 μg/mL
versus less than 14% in the control group for both sero-
types (Table 2) and 30.7% and 37.1% reached an OPA
titre ≥ 8 versus less than 11% in the control group
(Table 3). The anti-protein D antibody GMC was 44-
fold higher in the PHiD-CV (3791.8 EL.U/mL [95% CI:
3448.4-4169.3]) compared to the control group (85.4 EL.
U/mL [95% CI: 71.8-101.5]).
All children in both groups were seroprotected or ser-
opositive for antibodies against the DTPw-HBV/Hib
antigens except for 1 infant not seroprotected against
PRP in the control group and 2 infants not seropro-
tected against HBV in the PHiD-CV group (Table 4).
GMCs for anti-PRP and anti-tetanus antibodies were
higher in the PHiD-CV group than in the control group
(no overlap of 95% CIs), and the anti-diphtheria anti-
body GMC tended to be higher in the PHiD-CV group
(Table 4).
Reactogenicity and Safety
Overall incidences of solicited local events during the 4-
day post-vaccination period were similar between the
PHiD-CV and control groups (pain: 80.8% [95% CI:
77.7%-83.6%] versus 73.2% [95% CI: 68.3%-77.8%]; red-
ness: 10.9% [95% CI: 8.7%-13.4%] versus 10.3% [95% CI:
7.3%-13.9%]; swelling: 65.3% [95% CI: 61.7%-68.9%] ver-
sus 64.1% [95% CI: 58.8%-69.1%]). In both groups, pain
was the most frequently reported solicited local symptom
(Figure 2). In the PHiD-CV group, pain and swelling
were reported more frequently at the DTPw-HBV/Hib
than at the PHiD-CV injection site (Figure 2). Overall
incidences of solicited general events were similar
between the PHiD-CV and control groups (drowsiness:
3.8% [95% CI: 2.5%-5.5%] versus 3.7% [95% CI: 2.0%-
6.3%]; fever: 54.9% [95% CI: 51.1%-58.6%] versus 57.0%
[95% CI: 51.6%-62.2%]; irritability 47.9% [95% CI: 44.2%-
51.7%] versus 43.0% [95% CI: 37.8%-48.4%]; loss of appe-
tite 5.5% [95% CI: 4.0%-7.5%] versus 4.8% [2.8%-7.6%]).
Fever (axillary temperature ≥ 37.5°C) was the most com-
monly reported solicited general event in both groups,
with only 1 report of grade 3 fever (PHiD-CV group,
dose 3). Antipyretic medication use within 4 days post-
vaccination was frequent and similar in both groups (for
88.7% [95% CI: 86.1%-90.9%] of doses in the PHiD-CV







Gender (%), female/male 50.2/49.8 50.9/49.1 50.5/49.5
Dose 1:
mean age ± SD (weeks) 7.1 ± 1.14 7.0 ± 1.16 7.1 ± 1.14
mean weight ± SD (kg) 4.85 ± 0.76 4.74 ± 0.81 4.81 ± 0.78
mean weight-for-age Z-score ± SD -0.45 ± 1.10 -0.61 ± 1.17 -0.50 ± 1.13
Dose 2:
mean age ± SD (weeks) 12.2 ± 1.28 12.1 ± 1.33 12.1 ± 1.30
mean weight ± SD (kg) 5.80 ± 0.87 5.72 ± 0.93 5.78 ± 0.89
mean weight-for-age Z-score ± SD -0.39 ± 1.14 -0.49 ± 1.22 -0.43 ± 1.17
Dose 3:
mean age ± SD (weeks) 17.1 ± 1.25 17.0 ± 1.32 17.1 ± 1.27
mean weight ± SD (kg) 6.53 ± 0.90 6.39 ± 0.95 6.48 ± 0.92
mean weight-for-age Z-score ± SD -0.31 ± 1.08 -0.50 ± 1.17 -0.37 ± 1.11
Mean interval between dose 3 and blood sampling visit (days) 33.4 33.3 33.4
NOTE. SD, standard deviation; N, number of subjects
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Table 2 IgG antibody responses (22F-ELISA) against individual pneumococcal vaccine serotypes and cross-reactive
serotypes 6A and 19A (ATP immunogenicity cohort)
PHiD-CV group Control group
PHiD-CV serotypes N % ≥ 0.2 μg/mL (95% CI) GMC, μg/mL (95% CI) N % ≥ 0.2 μg/mL (95% CI) GMC, μg/mL (95% CI)
1 Pre-vaccine 204 19.6 (14.4-25.7) 0.07 (0.06-0.09) 110 18.2 (11.5-26.7) 0.07 (0.06-0.09)
Post-dose 3 217 100 (98.3-100) 2.69 (2.42-2.99) 108 1.9 (0.2-6.5) 0.03 (0.03-0.03)
4 Pre-vaccine 209 14.8 (10.3-20.4) 0.07 (0.06-0.08) 112 16.1 (9.8-24.2) 0.07 (0.06-0.08)
Post-dose 3 217 100 (98.3-100) 3.44 (3.06-3.87) 112 2.7 (0.6-7.6) 0.03 (0.03-0.03)
5 Pre-vaccine 210 17.6 (12.7-23.5) 0.07 (0.06-0.08) 111 19.8 (12.9-28.5) 0.07 (0.05-0.08)
Post-dose 3 217 100 (98.3-100) 4.17 (3.75-4.63) 109 3.7 (1.0-9.1) 0.03 (0.03-0.04)
6B Pre-vaccine 205 21.0 (15.6-27.2) 0.09 (0.07-0.10) 111 31.5 (23.0-41.0) 0.10 (0.08-0.12)
Post-dose 3 217 82.0 (76.3-86.9) 0.95 (0.76-1.20) 112 1.8 (0.2-6.3) 0.03 (0.03-0.03)
7F Pre-vaccine 207 27.1 (21.1-33.6) 0.09 (0.08-0.11) 111 23.4 (15.9-32.4) 0.08 (0.07-0.10)
Post-dose 3 217 99.5 (97.5-100) 3.33 (2.99-3.71) 110 1.8 (0.2-6.4) 0.03 (0.03-0.04)
9V Pre-vaccine 208 38.5 (31.8-45.4) 0.13 (0.11-0.16) 110 39.1 (29.9-48.9) 0.15 (0.11-0.19)
Post-dose 3 217 97.2 (94.1-99.0) 2.39 (2.06-2.76) 112 9.8 (5.0-16.9) 0.04 (0.03-0.05)
14 Pre-vaccine 206 87.9 (82.6-92.0) 0.75 (0.64-0.89) 110 84.5 (76.4-90.7) 0.76 (0.60-0.97)
Post-dose 3 217 99.1 (96.7-99.9) 3.80 (3.24-4.46) 112 35.7 (26.9-45.3) 0.14 (0.11-0.17)
18C Pre-vaccine 204 36.3 (29.7-43.3) 0.12 (0.10-0.15) 110 34.5 (25.7-44.2) 0.12 (0.09-0.15)
Post-dose 3 217 99.5 (97.5-100) 10.01 (8.49-11.80) 112 3.6 (1.0-8.9) 0.03 (0.03-0.04)
19F Pre-vaccine 208 68.3 (61.5-74.5) 0.33 (0.28-0.40) 111 68.5 (59.0-77.0) 0.36 (0.29-0.45)
Post-dose 3 217 98.6 (96.0-99.7) 7.65 (6.55-8.93) 111 22.5 (15.1-31.4) 0.08 (0.07-0.10)
23F Pre-vaccine 202 29.2 (23.0-36.0) 0.08 (0.07-0.10) 108 31.5 (22.9-41.1) 0.10 (0.07-0.12)
Post-dose 3 217 87.6 (82.4-91.6) 1.10 (0.91-1.33) 112 2.7 (0.6-7.6) 0.03 (0.03-0.04)
Cross-reactive serotypes
6A Pre-vaccine 208 34.1 (27.7-41.0) 0.13 (0.11-0.15) 112 35.7 (26.9-45.3) 0.14 (0.11-0.18)
Post-dose 3 217 25.8 (20.1-32.2) 0.09 (0.08-0.11) 108 7.4 (3.3-14.1) 0.04 (0.04-0.05)
19A Pre-vaccine 205 48.3 (41.3-55.4) 0.18 (0.15-0.22) 110 44.5 (35.1-54.3) 0.20 (0.15-0.26)
Post-dose 3 217 43.8 (37.1-50.7) 0.15 (0.13-0.18) 108 13.9 (8.0-21.9) 0.06 (0.05-0.07)
NOTE. GMC, geometric mean antibody concentration; pre-vaccine, before the first vaccine dose; post-dose 3, 1 month after vaccine dose 3; N, number of subjects
with available results (this number varies per time point and per serotype depending on the amount of serum available for testing).
Table 3 OPA responses against individual pneumococcal vaccine serotypes and cross-reactive serotypes 6A and 19A 1
month after 3-dose primary vaccination (ATP immunogenicity cohort)
PHiD-CV group Control group
PHiD-CV serotypes N % ≥ 8 (95% CI) GMT (95% CI) N % ≥ 8 (95% CI) GMT (95% CI)
1 105 87.6 (79.8-93.2) 83.0 (61.7-111.7) 56 5.4 (1.1-14.9) 5.0 (3.8-6.4)
4 105 100 (96.5-100) 892.5 (759.4-1049.0) 55 5.5 (1.1-15.1) 4.6 (3.9-5.5)
5 105 95.2 (89.2-98.4) 82.7 (65.4-104.4) 56 3.6 (0.4-12.3) 4.5 (3.8-5.2)
6B 103 85.4 (77.1-91.6) 538.6 (346.0-838.3) 54 9.3 (3.1-20.3) 5.7 (4.1-7.9)
7F 105 100 (96.5-100) 2733.0 (2188.3-3413.3) 49 42.9 (28.8-57.8) 31.5 (15.5-64.0)
9V 105 98.1 (93.3-99.8) 1023.7 (784.8-1335.2) 54 24.1 (13.5-37.6) 8.4 (5.8-12.4)
14 104 96.2 (90.4-98.9) 1079.2 (776.0-1500.9) 53 24.5 (13.8-38.3) 8.9 (5.7-14.1)
18C 105 98.1 (93.3-99.8) 617.6 (495.3-770.0) 56 3.6 (0.4-12.3) 4.4 (3.8-5.2)
19F 105 96.2 (90.5-99.0) 358.3 (269.9-475.5) 56 3.6 (0.4-12.3) 4.6 (3.8-5.7)
23F 104 93.3 (86.6-97.3) 881.8 (615.0-1264.4) 53 9.4 (3.1-20.7) 6.6 (4.2-10.3)
Cross-reactive serotypes
6A 101 30.7 (21.9-40.7) 14.1 (9.4-21.2) 56 10.7 (4.0-21.9) 6.1 (4.4-8.7)
19A 105 37.1 (27.9-47.1) 11.0 (8.3-14.6) 56 5.4 (1.1-14.9) 4.3 (4.0-4.6)
NOTE. GMT, geometric mean titre; N, number of subjects with available results.
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Table 4 Immune responses against DTPw-HBV/Hib vaccine antigens 1 month after 3-dose primary vaccination (ATP
immunogenicity cohort)
PHiD-CV group Control group
Antigen (cut-off) N % (95% CI) GMC (95% CI) N % (95% CI) GMC (95% CI)
Diphtheria toxoid (0.1 IU/mL) 110 100 (96.7-100) 4.103 (3.527-4.773) 112 100 (96.8-100) 3.130 (2.731-3.588)
Tetanus toxoid (0.1 IU/mL) 110 100 (96.7-100) 6.484 (5.511-7.628) 112 100 (96.8-100) 4.588 (3.880-5.426)
Bordetella pertussis (15 EL.U/mL) 110 100 (96.7-100) 111.9 (102.0-122.7) 111 100 (96.7-100) 124.9 (111.7-139.7)
HBs (10 mIU/mL) 91 97.8 (92.3-99.7) 1835.1 (1384.0-2433.2) 96 100 (96.2-100) 1485.5 (1198.7-1840.9)
PRP (0.15 μg/mL) 110 100 (96.7-100) 18.461 (14.256-23.907) 112 99.1 (95.1-100) 10.137 (7.515-13.673)
NOTE. GMC, geometric mean antibody concentration; HBs, hepatitis B surface antigen; PRP, Haemophilus influenzae type b polyribosylribitol phosphate; N,
number of subjects with available results
Figure 2 Local symptoms. Percentage of doses followed by pain (A), redness (B) and swelling (C) at the specified injection site of any intensity
and grade 3 intensity (hatched areas) (ATP immunogenicity cohort). Error bars indicate 95% CIs. Grade 3 pain: crying when limb was moved/
spontaneously painful; grade 3 redness/swelling: diameter > 30 mm.
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group and 87.2% [95% CI: 83.2%-90.5%] in the control
group). Antipyretic medication was taken prophylacti-
cally for 9.6% (95% CI: 7.5%-12.0%) of the vaccine doses
in the PHiD-CV group and 8.5% (95% CI: 5.8%-12.0%) in
the control group.
The incidences of grade 3 solicited general symptoms
(Figure 3) and grade 3 pain and redness (Figure 2) fol-
lowing each vaccine dose were low (≤2.9%) in both
groups. The incidence of grade 3 swelling at the PHiD-
CV injection site was also low (≤0.4%) while grade 3
swelling at the DTPw-HBV/Hib injection site was 5.4%
and 5.9% in PHiD-CV and control group respectively
after the first dose and ≤2.1% after subsequent doses
(Figure 2).
The percentage of doses followed by at least 1 unsoli-
cited AE was similar in both groups (following 53.0%
[95% CI: 49.3%-56.8%] of doses in the PHiD-CV group
and 57.3% [95% CI: 51.9%-62.5%] in the control group).
The most common unsolicited AEs were gastroenteritis
(9.8% [95% CI: 7.7%-12.2%] in PHiD-CV group, 10.3%
[95% CI: 7.3%-13.9%] in control group), rhinitis (16.0%
[95% CI: 13.4%-18.9%] and 14.8% [95% CI: 11.3%-
19.0%]) and rhinobronchitis (15.0% [95% CI: 12.4%-
17.8%] and 16.2% [95% CI: 12.5%-20.5%]). Unsolicited
AEs with a causal relationship to vaccination were
reported following 5.7% (95% CI: 4.1%-7.6%) of doses in
the PHiD-CV group and 9.7% (95% CI: 6.8%-13.3%] of
doses in the control group (mainly injection site indura-
tion; following 4.1% and 6.8% of doses, respectively).
The incidence of grade 3 unsolicited AEs was low, fol-
lowing 1.1% of doses in both groups, and none was con-
sidered to be causally related to vaccination.
Seven SAEs were reported in 5 children in the PHiD-
CV group (4 cases of bronchopneumonia, 1 case of
Figure 3 General symptoms. Percentage of doses followed by drowsiness (A), fever (B), irritability (C) and loss of appetite (D) of any intensity
and grade 3 intensity (hatched areas) (ATP immunogenicity cohort). Error bars indicate 95% CIs. Grade 3 drowsiness: prevented normal activity;
grade 3 fever: axillary temperature > 39.5°C; grade 3 irritability: crying that could not be comforted/prevented normal activity; grade 3 loss of
appetite: child did not eat at all.
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malaria, 1 case of febrile convulsions and 1 head injury
[haematoma] secondary to a car accident) and none in
the control group. None of the SAEs were considered to
be causally related to vaccination and all infants recov-
ered without sequelae.
Discussion
Pneumococcal conjugate vaccines, including PHiD-CV,
are being introduced in African countries under the
Advance Market Commitments for pneumococcal disease
piloted by GAVI [2]. In our study, PHiD-CV was immuno-
genic for all vaccine pneumococcal serotypes and NTHi
protein D when given as a 3-dose primary vaccination
course at 6, 10 and 14 weeks of age and co-administered
with DTPw-HBV/Hib and OPV to Malian and Nigerian
infants. Vaccine tolerability was comparable between the
group administered PHiD-CV and the control group
administered DTPw-HBV/Hib and OPV only.
One month after PHiD-CV primary vaccination at 6, 10
and 14 weeks of age, for each of the 10 vaccine serotypes
high percentages of infants had an antibody concentration
≥ 0.2 μg/mL and an OPA titre ≥ 8. For several serotypes,
this was despite high percentages of infants with pre-vacci-
nation antibody concentration ≥ 0.2 μg/mL. These
immune responses are consistent with previous primary
vaccination studies in which PHiD-CV was administered
using the same schedule [15] or at 2, 4 and 6 months of
age [15,20-22]. As in other pneumococcal conjugate vac-
cine studies [8,14,29-33], serotype 6B was one of the low
immunogenic serotypes. However, pneumococcal conju-
gate vaccine trials have reported high efficacy against IPD
or acute otitis media even for serotypes with lower anti-
body responses [8,14,29,30,34]. The high proportions of
infants with a pre-vaccination antibody concentration ≥
0.2 μg/mL we observed in this study for several vaccine
serotypes can probably be explained by maternal antibo-
dies transferred during the last months of pregnancy
rather than early exposure to S. pneumoniae, given that
antibody concentrations and percentages of infants with
antibody concentration ≥ 0.2 μg/mL significantly declined
in the control group by the time of post-vaccination blood
draw at approximately 5 months of age. Our data however
indicate that the presence of these high levels of maternal
antibodies did not hamper immune responses to early
infant PHiD-CV primary vaccination. It is well known that
pneumococcal exposure and acquisition of pneumococcal
nasopharyngeal carriage may start very early in sub-
Saharan infant populations [35,36] and recent publications
have indicated that pneumococcal colonization at the time
of primary vaccination could possibly have a negative
impact on infant pneumococcal conjugate vaccine
responses [37-39]. Our results therefore seem to support
the need to maintain early vaccination with pneumococcal
conjugate vaccines in this population.
Anti-pneumococcal immune responses in this popula-
tion of infants tended to be higher than those observed
in European PHiD-CV primary vaccination studies
[15,18,20]. A PHiD-CV study conducted in Chile also
reported stronger immune responses for all serotypes
compared to European data [21] and a study of PHiD-CV
conducted in the Philippines and Poland found greater
immunogenicity in Filipino infants [15] despite the use of
an accelerated schedule compared to the more immuno-
genic 2, 4 and 6 months schedule in Poland. Genetic fac-
tors, early exposure to pneumococcal serotypes or
nasopharyngeal carriage of pneumococcal serotypes
might have contributed to this effect [40].
Good immune responses were also observed against
DTPw-HBV/Hib, which was consistent with another study
of PHiD-CV co-administered with DTPw-HBV/Hib
[15,28], and proportions of infants who were seroprotected
or seropositive for antibodies against the DTPw-HBV/Hib
antigens were high (≥ 97.8%). Antibody concentrations
against the PRP, tetanus and diphtheria antigens were
higher when PHiD-CV was co-administered, presumably
due to enhancement of these immune responses by the
tetanus toxoid and diphtheria toxoid carrier proteins used
for serotypes 18C and 19F, respectively, in PHiD-CV [28].
High antibody GMCs and seroprotection rates were how-
ever observed for these antigens in both groups, including
the PRP antigen, confirming the good immunogenicity of
a reduced PRP content Hib vaccine (2.5 μg of PRP) com-
pared to the more usual 10 μg PRP vaccines [41-45].
Addition of PHiD-CV to the routine EPI vaccination
schedule at 6, 10 and 14 weeks of age did not result in
increased incidences of AEs (solicited or unsolicited)
relative to DTPw-HBV/Hib and OPV administered alone
in the control group. There were no SAEs considered
causally related to the vaccines. The overall incidences of
solicited symptoms were similar between the 2 groups,
with pain and fever being the most frequently reported
local and general symptoms. The incidences of pain and
swelling were higher at the DTPw-HBV/Hib injection
site than at the PHiD-CV injection site, which was in line
with another study of PHiD-CV or 7vCRM co-adminis-
tered with a DTPw-based vaccine [15,16]. Prophylactic
use of antipyretics is recommended when PHiD-CV is
co-administered with whole-cell pertussis containing vac-
cines [46]. In our study, antipyretic medication use at the
time of vaccination was common in both groups (for 87-
89% of the doses) and antipyretic prophylaxis was used in
8-10% of vaccine doses, with similar prophylactic anti-
pyretic use after each dose (data not shown). The inci-
dences of grade 3 solicited symptoms were low, apart
from the incidence of grade 3 swelling at the DTPw-
HBV/Hib injection site after the first vaccine dose. The
overall incidence of unsolicited AEs was also comparable
between groups and the most frequent unsolicited AEs
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reported were in line with events expected in the paedia-
tric age group studied.
Conclusion
PHiD-CV was immunogenic for all vaccine pneumococ-
cal serotypes and NTHi protein D in Malian and Niger-
ian infants when given as a 3-dose primary vaccination
course according to the routine EPI vaccination sche-
dule at 6, 10 and 14 weeks of age and co-administered
with DTPw-HBV/Hib and OPV. Tolerability was gener-
ally comparable between the PHiD-CV and control vac-
cination groups and pain and swelling were less
frequent at the PHiD-CV injection site compared to the
DTPw-HBV/Hib injection site. These data provide valu-
able information for PHiD-CV paediatric use in sub-
Saharan African settings.
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